Abstract 5658
Background
A convenient and accurate method to improve the effectiveness of colorectal-cancer screening is still under exploration. This may be achieved by a diagnostic model based on 5-hydroxymethylcytosine (5-hmC).
Methods
We collected peripheral venous blood from 285 colorectal cancer patients and 285 healthy people at Zhongshan Hospital, Shanghai. The 5-hmC level of each gene locus in circulating-free DNA (cfDNA) was detected using a highly sensitive sequencing method. Of 285 subjects, 178 in each group were randomly selected as training set. The first 100 gene loci with the most significant difference of 5-hmC level were selected for establishing a diagnostic model (Logistic regression model) based on machine-learning method. The rest subjects in each group were used as validating set to validate this model. Further, we analysed the influence of several clinicopathological factors on 5-hmC level.
Results
In training set, the comprison of the 5-hmC level suggested that the expression of 5-hmC in cfDNA was significantly different between the two groups. Of the 100 gene loci, 35 were included in the model. In internal validation, the sensitivity and specificity of the model were 88.8% and 89.9%, respectively. While the sensitivity and specificity 81.3% and 89.7%, respectively, in external validation using the validating set. The area under ROC curve of external validation was 0.946. For colorectal cancer stages I-IV, the diagnostic sensitivities were 78.7%, 81.9%, 88.2% and 95.6%, respectively. We also found that age, gender, Ras status or the site of primary tumor had no significant effect on the expression of 5-hmC. However, there was a statistically difference of 5-hmC level between stage I-III and stage IV.
Conclusions
Our study identified the gene loci with significantly different 5-hmC level between colorectal cancer patients and healthy people, then we established a diagnostic model of colorectal cancer with high sensitivity and specificity. However, the utility of the model still need further verification in large-scale screening experiments.
Clinical trial identification
NCT03599947 09/16/2018.
Editorial acknowledgement
Shanghai Yibien Gene Technology Co., Ltd. Provides Testing Platform.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3907 - Exploration of efficacious alternative regorafenib regimens to manage hand-foot-skin-reaction (HFSR)
Presenter: Axel Grothey
Session: Poster Display session 2
Resources:
Abstract
3958 - Quality of Life (QoL) in Metastatic Colorectal Cancer (mCRC) in the Real World: Final Results of a European Survey
Presenter: Zorana Maravic
Session: Poster Display session 2
Resources:
Abstract
3563 - BISQUIT: A Randomized Phase II Study of the Administration of Prebiotics and Probiotics During Definitive Treatment With Chemotherapy-radiotherapy for Patients With Squamous Cell Carcinoma of the Anal Canal
Presenter: Rachel Riechelmann
Session: Poster Display session 2
Resources:
Abstract
1184 - iSCORE: Immunotherapy Sequencing in COlon and REctal Cancer
Presenter: Fiona Turkes
Session: Poster Display session 2
Resources:
Abstract
3346 - Phase II study of preoperative (PREOP) chemoradiotherapy (CTRT) plus avelumab (AVE) in patients (PTS) with locally advanced rectal cancer (LARC): The AVANA Study
Presenter: Lisa Salvatore
Session: Poster Display session 2
Resources:
Abstract
3895 - A phase II study of capecitabine plus concomitant radiation therapy followed by durvalumab (MEDI4736) as preoperative treatment in rectal cancer: PANDORA study.
Presenter: Maria Aurelia Barbera
Session: Poster Display session 2
Resources:
Abstract
2012 - Open Label Phase III Study of Arfolitixorin vs. Leucovorin in mFOLFOX-6 for First Line Treatment of Metastatic Colorectal Cancer: AGENT
Presenter: Josep Tabernero
Session: Poster Display session 2
Resources:
Abstract
2198 - SOLSTICE, a phase 3, randomized, open label study of trifluridine/tipiracil+bevacizumab (bev) versus capecitabine+bev for the 1L treatment of patients with unresectable metastatic colorectal cancer (mCRC) who are not candidates for intensive therapy
Presenter: Thierry Andre
Session: Poster Display session 2
Resources:
Abstract
2921 - A Phase Ib/ II Trial to Assess the Safety and Efficacy of CXD101 in Combination with the PD-1 Inhibitor Nivolumab in Patients with Metastatic, Previously-Treated, Microsatellite-Stable (MSS) Colorectal Carcinoma (short title CAROSELL)
Presenter: Mark Saunders
Session: Poster Display session 2
Resources:
Abstract
3695 - A Phase 1b/2 Study of Onvansertib (PCM-075) in Combination with FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer in Patients with a KRAS Mutation
Presenter: Heinz Josef Lenz
Session: Poster Display session 2
Resources:
Abstract